

Covalon Technologies Ltd. to Participate in the 2024 Association for Vascular Access Annual Scientific Meeting

Visit Covalon at booth 523 to discover the latest in compassionate vascular access solutions

MISSISSAUGA, Ontario – September 27, 2024 – (BUSINESS WIRE) – Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), is pleased to announce its participation in the 2024 Association for Vascular Access ("AVA") Annual Scientific Meeting. The event will take place from September 28 to 30 in Colorado. Founded in 1985, AVA's multidisciplinary membership is dedicated to advancing research, providing education, and fostering collaboration to improve patient outcomes in vascular access. Covalon is proud to be a part of this esteemed community and to contribute to the development of evidence-based innovations.

"Our participation in the AVA Annual Scientific Meeting highlights Covalon's commitment to enhancing patient comfort and supporting improved vascular access clinical care," said Brent Ashton, Chief Executive Officer, Covalon. "Our silicone-adhesive dressings help to reduce the challenges of cumbersome acrylic dressing removals, while our vascular access line guard helps to protect against gross contamination. Together, these products combine safety, compassion, and innovation to help improve clinical outcomes."



At booth #523, Covalon will be showcasing its comprehensive range of compassionate vascular access solutions, including a new range of CovaClear® IV Vascular Access Dressings. Attendees are invited to learn more about how these innovative products are helping healthcare providers deliver exceptional care to patients around the world. Covalon representatives will be available to discuss the latest advancements in vascular access technology and answer any questions.

Covalon's patented vascular access products include:

- [VALGuard®](#) - a transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids and other secretions.
- [SurgiClear®](#) - a dual antimicrobial clear silicone adhesive dressing with Chlorhexidine and Silver used to cover and protect wound sites and wound closure devices.
- [IV Clear®](#) - a dual antimicrobial (Chlorhexidine and Silver) clear IV securement dressing that provides antimicrobial protection throughout the entire dressing surface area.

covalon

- [CovaClear® IV](#) - a soft silicone adhesive clear IV dressing that helps protect insertion sites from external contaminants. Suitable for patients who either don't require, or cannot tolerate, antimicrobials.

Scheduling Appointments and Additional Information

To book an appointment with a Covalon representative, please email Ron Hebert, SVP Growth, Covalon Technologies Ltd., at rhebert@covalon.com.

Conference Details

- Dates: September 28 – 30 2024
- Location: Gaylord Rockies Resort & Convention Center, 6700 N Gaylord Rockies Blvd, Aurora, CO 80019, United States
- Registration: <https://avasm24.eventscribe.net>

For healthcare providers unable to attend the conference, Covalon encourages you to visit www.covalon.com or follow the company on [LinkedIn](#), [Facebook](#), or [Instagram](#) to learn more about its solutions.

To learn more about Covalon, please contact:

Investor Relations, Covalon Technologies Ltd.

Email: investors@covalon.com

Website: <https://covalon.com/>

About Covalon

Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions for advanced wound care, infection control, and medical device coatings. Through a strong portfolio of patented technologies and solutions, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events.



Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

SOURCE Covalon Technologies Ltd.